With 1.28 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.32 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $1.0798 whereas the lowest price it dropped to was $0.9652. The 52-week range on NMTC shows that it touched its highest point at $1.39 and its lowest point at $0.40 during that stretch. It currently has a 1-year price target of $2.23. Beta for the stock currently stands at 0.60.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NMTC was up-trending over the past week, with a rise of 10.62%, but this was up by 25.58% over a month. Three-month performance surged to 34.74% while six-month performance rose 109.60%. The stock gained 20.55% in the past year, while it has gained 2.64% so far this year. A look at the trailing 12-month EPS for NMTC yields -0.16 with Next year EPS estimates of -0.14. For the next quarter, that number is -0.04. This implies an EPS growth rate of 75.00% for this year and -26.09% for next year. EPS is expected to grow by 37.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 23.14%.
Float and Shares Shorts:
At present, 49.82 million NMTC shares are outstanding with a float of 44.07 million shares on hand for trading. On 2025-09-15, short shares totaled 29860.0, which was 5.9999997 higher than short shares on 1755216000. In addition to Mr. David A. Rosa M.D. as the firm’s President, CEO & Director, Mr. Ronald W. McClurg serves as its Chief Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, NMTC reported revenue of $1696050.0 and operating income of -$1886600.0. The EBITDA in the recently reported quarter was -$1744574.0 and diluted EPS was -$0.03.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With NMTC analysts setting a high price target of 3.0 and a low target of 1.45, the average target price over the next 12 months is 2.225. Based on these targets, NMTC could surge 200.0% to reach the target high and rise by 45.0% to reach the target low. Reaching the average price target will result in a growth of 122.5% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.35585 being high and -$0.46415 being low. For NMTC, this leads to a yearly average estimate of -$0.41. Based on analyst estimates, the high estimate for the next quarter is -$0.03 and the low estimate is -$0.04. The average estimate for the next quarter is thus -$0.04.
